This page shows the latest ICOs news and features for those working in and with pharma, biotech and healthcare.
Jounce now takes back full worldwide rights to the rest of its pipeline, including the ICOS-targeting vopratelimab, PD-1 inhibitor JTZ-4014 and all discovery programmes. ... BMS has its own anti-ICOS agonist, BMS-986226, in clinical trials and the
Courses on offer include What you need to know about NHS England's plan for ICSs and ICOs, which addresses how integrated care systems and integrated care organisations will start to
Key to the future of the health service in England will be the Integrated Care Organisations (ICOs), which aim to bring together health and social care services, both to improve patient ... At the moment there are 12m people in England covered by ICOs
the lack of a legal framework is hampering the ICOs from making faster progress. ... Secondly, there has been considerable resistance against the changes, with campaigners claiming ICOs/ACSs are another backdoor privatisation of the NHS.
That includes data on Jounce Therapeutics’ ICOS-targeting antibody JTX-2011 which disappointed investors when the ASCO abstract was made public earlier this month, as well as Celldex’ anti-CD27 agonist
Standout examples of that this year include Jounce Therapeutics - which fell dramatically after data from a phase I trial of its ICOS agonist antibody JTX-2011 alongside Bristol-Myers Squibb’s
More from news
Approximately 1 fully matching, plus 18 partially matching documents found.
Key to the future of the health service in England will be the Integrated Care Organisations (ICOs), which aim to bring together health and social care services, both to improve patient ... At the moment there are 12 million people in England covered by
ICOs (formerly known as Accountable Care Systems) require exceptional individuals who can break down the many institutional, cultural and financial barriers between hospitals, primary care and local authorities.
It is a humanised inducible co-stimulator (ICOS) agonist antibody, designed to both stimulate T effector cells and selectively reduce intra-tumoural T regulatory cells.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
New courses on offer include: “What do you need to know about NHS England's plan for ICSs and ICOs?”, which addresses how integrated care systems and integrated care organisations will
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...